Urinary proteomics and drug discovery in chronic kidney disease: A new perspective

Marco Prunotto, Gian Marco Ghiggeri, Giovanni Candiano, Pierre Lescuyer, Denis Hochstrasser, Solange Moll

Research output: Contribution to journalArticlepeer-review


Chronic kidney disease (CKD) is becoming a worldwide public health problem. The identification of a specific set of early biomarkers for CKD is extremely relevant to progress in disease knowledge, improving diagnosis, treatment, or development, and monitoring efficacy of new drugs. As kidney fibrosis can be considered the common pathological way to end stage renal failure, independent of the initial renal insult, these biomarkers are therefore biomarkers of early tubulo-interstitial fibrosis. The availability of a specific set of biomarkers for CKD is the mandatory condition to create new dedicated drugs and validate them in clinics without waiting years for a functional response in patients. We suggest here specific cohorts of patients where this early signature of fibrosis may be simpler to be identified.

Original languageEnglish
Pages (from-to)126-132
Number of pages7
JournalJournal of Proteome Research
Issue number1
Publication statusPublished - Jan 7 2011


  • Biomarker
  • CKD
  • Drug discovery
  • Proteomics
  • Urine

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Fingerprint Dive into the research topics of 'Urinary proteomics and drug discovery in chronic kidney disease: A new perspective'. Together they form a unique fingerprint.

Cite this